PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26479717-0	2016	Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder.	Buprenorphine	160-173	SURP and G-patch domain containing 1	Homo sapiens	70-73	
26479717-1	2016	RBP-6000 is a novel sustained-release formulation of buprenorphine for the treatment of opioid use disorder, which has been designed for once-monthly (28 days) subcutaneous (SC) injections.	Buprenorphine	53-66	SURP and G-patch domain containing 1	Homo sapiens	0-3	
26479717-2	2016	A population pharmacokinetic (PK) model was developed to describe the time course of buprenorphine plasma concentrations after repeated SC injections of RBP-6000 at 50 mg, 100 mg, 200 mg, or 300 mg in treatment-seeking opioid-dependent subjects previously on sublingual buprenorphine (Subutex( ) ) treatment.	Buprenorphine	85-98	SURP and G-patch domain containing 1	Homo sapiens	153-156	
26650971-0	2016	Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder.	Buprenorphine	18-31	SURP and G-patch domain containing 1	Homo sapiens	33-36	
26650971-2	2016	Buprenorphine, a mu-opioid receptor partial agonist and kappa opioid receptor antagonist, is now being developed as a monthly, sustained-release formulation (RBP-6000).	Buprenorphine	0-13	SURP and G-patch domain containing 1	Homo sapiens	158-161	
25015174-0	2014	A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence.	Buprenorphine	197-210	SURP and G-patch domain containing 1	Homo sapiens	107-110	
25015174-1	2014	BACKGROUND AND OBJECTIVES: This study implemented pharmacokinetic/pharmacodynamic modelling to support the clinical development of RBP-6000, a new, long-acting, sustained-release formulation of buprenorphine for the treatment of opioid dependence.	Buprenorphine	194-207	SURP and G-patch domain containing 1	Homo sapiens	131-134	
25015174-10	2014	Model simulations indicated that a 200 mg RBP-6000 dose should achieve 2-3 ng/mL buprenorphine average concentrations and desired efficacy.	Buprenorphine	81-94	SURP and G-patch domain containing 1	Homo sapiens	42-45